Adventitious agents in viral vaccines: Lessons learned from 4 case studies

Biologicals

Volumn 42, Issue 5, 2014, Pages 223-236

  Petricciani, John ^a   Sheets, Rebecca ^b   Griffiths, Elwyn ^c   Knezevic, Ivana ^d  

^a IABs   (United States)

^b Grimalkin Partners   (United States)

^c WHO L276 ^*  (United Kingdom)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adventitious agents; Regulatory preparedness; Vaccines; Viral contamination

Indexed keywords

MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; RNA DIRECTED DNA POLYMERASE; ROTAVIRUS VACCINE; VIRUS ANTIBODY; VIRUS DNA; VIRUS VACCINE; BIOLOGICAL PRODUCT; MEASLES MUMPS RUBELLA VACCINE;

BACTERIOPHAGE; CASE STUDY; CIRCOVIRUS; DNA SEQUENCE; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INTERPERSONAL COMMUNICATION; MEASLES; MUMPS; NONHUMAN; OUTCOME ASSESSMENT; POLIOMYELITIS; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; ROTAVIRUS INFECTION; SIMIAN VIRUS 40; VACCINE PRODUCTION; VIRAL CONTAMINATION; VIRUS INFECTION; VIRUS INFECTIVITY; WORLD HEALTH ORGANIZATION; ANIMAL; DRUG CONTAMINATION; GENETICS; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL; PUBLIC HEALTH; STANDARDS;

ANIMALS; BACTERIOPHAGES; BIOLOGICAL PRODUCTS; CIRCOVIRUS; DNA, VIRAL; DRUG CONTAMINATION; HUMANS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; POLIOVIRUS VACCINES; PUBLIC HEALTH; RNA-DIRECTED DNA POLYMERASE; ROTAVIRUS VACCINES; SIMIAN VIRUS 40; VIRAL VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84908211470     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2014.07.003     Document Type: Review

References (56)

1. Regulatory risk evaluation on finding an adventitious agent in a marketed vaccine: scientific principles to consider. http://www.who.int/biologicals.
2. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Replacement of TRS 878 2013, World Health Organization, Geneva, Annex 1. Annex 3 in WHO Expert Committee on Biological Standardization. Sixty-first report. WHO Technical Report Series, No. 978.
3. Stewart S.E., Eddy B.E., Gochenour A.M., Borgese N.G., Grubbs G.E. The induction of neoplasms with a substance released from mouse tumors by tissue culture. Virology 1957 Apr, 3(2):380-400.
4. Eddy B.E., Stewart S.E., Mider C.B. Neoplasms in hamster induced by mouse tumor agent passed in tissue culture. JNatl Cancer Inst 1958, 20:747-760.
5. Hearings before the subcommittee on executive reorganization and government research of the committee on government operations. United States Senate. 93rd Congress April 20, 21, 1972 and May 3, 4, 1972, 549-550. U.S Government Printing Office, Washington.
6. Sweet B.H., Hilleman M.R. The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 1960 Nov, 105:420-427.
7. Hilleman M.R. Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand 1998, 94:183-190.
8. Galambos L., Sewel J.E. Networks of innovation: vaccine development at merck 1895-1995, 79-83. Cambridge University Press 1995, Sharp and Dohme, and Mulford.
9. Goffe A.P., Hale J., Gardner P.S. Poliomyelitis vaccines. Lancet 1961 18 Mar, 277(7177):612.
10. Morris J.A., Johnson K.M., Aulisio C.G., Chanock R.M., Knight V. Clinical and serological responses in volunteers given vacuolating virus (OSV40) by respiratory route. Proc Soc Exp Biol Med 1961, 108:613-616.
11. Gerber P., Hottle G.A., Grubbs R.E. Inactivanon of vacuolating virus (SV40) by formaldehyde. Proc Soc Exp Biol Med 1961, 108:205-209.
12. Requirements for Biological Substances 7 Requirements for poliomyelitis vaccine (oral): report of a study group 1962, WHO Technical Report series No 237.
13. Report of the technical committee on poliomyelitis vaccine: presence of vacuolating agent in poliomyelitis vaccine May 18, 1961, Merck Archives.
14. Eddy B.E., Borman G.S., Berkeley W.H., Young R.D. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med 1961 May, 107:191-197.
15. Report of the technical committee on poliomyelitis vaccine: presence of vacuolating agent in poliomyelitis vaccine June 20, 1961, Merck Archives.
16. Hearings before a Subcommittee of the Committee on Interstate and Foreign Commerce of the House of Representatives Developments with respect to the manufacture of live poliovirus vaccine and results of utilization of killed virus polio vaccine Mar. 16 and 17, 1961, Washington, D.C.: GPO, 1961, Appendix K. http://babel.hathitrust.org/cgi/pt?id=mdp.35112104240587;view=1up;seq=475.
17. Department of Health, Education, and Welfare, National institutes of health division of biologics standards Conference on production and testing and requirements for live poliovirus vaccine Aug. 18-19 1960, Day 1: pp. 16-22, 89-92, 94, 101; Day 2: pp. 44-54, 58, 60-69, 97-112.
18. Code of Federal Regulations Part 73 biological products, safety standards: poliomyelitis vaccine, adenovirus vaccine March 5, 1963, 2109.
19. Sierra-Honigmann A., Krause P.R. Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA. Biologicals 2000, 28(1):1-4.
20. Sweet B.H., Hilleman M.R. Detection of a 'Non-Detectable' simian virus (vacuolating agent) present in rhesus and cynomolgus monkey kidney cell culture material: a preliminary report. Second International Conference on Live Poliovirus Vaccines June 6-, 1960, 79-85. Pan American Health Organization and the World Health Organization, Washington, DC.
21. Koprowski H. Live poliovirus vaccines - present status and problems for the future. JAm Med Assoc 1961, 178(12):1151-1155.
22. Butel J.S. Simian virus 40, polio vaccines, and human caner: research progressversus media and public interest. Bull World Health Organ 2000, 78(2):185-187.
23. Merril C.R., Friedman T.B., Attallah A.F., Geier M.R., Krell K., Yarkin R. Isolation of bacteriophages from commercial sera. InVitro 1972, 8(2):91-93.
24. Chu F.C., Johnson J.B., Orr H.C., Probst P.G., Petricciani J.C. Bacterial virus contamination of fetal bovine sera. InVitro 1973, 9:31-34.
25. Petricciani J.C., Chu F.C., Johnson J.B. Bacteriophages in live virus vaccines. Proc Soc Exp Biol Med 1973, 144(3):789-792.
26. Haselkorn R., Schichman S., Milstien J., Petricciani J. Characteristics of bacteriophage NV-1 isolated from live virus vaccines. Proc Soc Exp Biol Med 1978, 158(3):383-387.
27. Ad hoc advisory committee: Thomas F. Anderson (Institute for Cancer Research), Edward L. Buescher (Walter Reed Army Institute of Research), Seymour Cohen (University of Colorado), Harry Eagle (Albert Einstein College of Medicine), Robert Haselkorn (University of Chicago), Samuel L. Katz (Duke University School of Medicine), Saul Krugman (New York University), Edwin H. Lennette (California State Department of Health), Albert Sabin (Fogarty International Center), John Seal (National Institute of Allergy and Infectious Diseases), and David J. Sencer (Center for Disease Control).
28. Federal Register Certain viral vaccines containing unavoidable bacteriophage 1973, vol. 38:11080-11081.
29. Boyd L.S.K., Portnoy B. Bacteriophage treatment in bacillary dysentery. Trans R Soc Trop Med Hyg 1944, 37:243.
30. Dutta N.K., Panse M.V. An experimental study on the usefulness of bacteriophage in the prophylaxis and treatment of cholera. Bull World Health Organ 1963, 28(3):357-360.
31. Ochs H.D., Davis S.O., Wedgwood R.J. Immunologic responses to bacteriophage NX-174 in immunodeficiency diseases. JClin Invest Dec 1971, 50(12):2559-2568.
32. Petricciani J.C., Hsu T.C., Stock A.D., Turner J.H., Wenger S.L., Elisberg B.L. Bacteriophages, vaccines, and people: an assessment of risk. Proc Soc Exp Biol Med 1978, 158(3):378-382.
33. Milstien J.B., Walker J.R., Petricciani J.C. Bacteriophages in live virus vaccines: lack of evidence for effects on the genome of rhesus monkeys. Science 1977, 197(4302):469-470.
34. Wenger S.L., Turner J.H., Petricciani J.C. The cytogenetic, proliferative and viability effects of four bacteriophages on human lymphocytes. InVitro 1978, 14(6):543-549.
35. Pyra H., Boni J., Schubach J. Ultrasenstivie retrovirus detection by a reverse-transcriptase assay based on product enhancement. Proc Natl Acad Sci U S A 1994, 91:1544-1548.
36. Reverse transcriptase activity in chicken-cell derived vaccines July 1998, 209-216. WHO Weekly Epidemiological Record 73.
37. WHO Expert committee on biological standardization 1998, vol. 897. 49th Report WHO Technical Report Series.
38. Shahbuddin M., Sears J.F., Khan A.S. No evidence of infectious retroviruses in measles virus vaccines produced in chicken embryo cell cultures. JClin Microbiol 2001, 39(2):675-684.
39. WHO Expert committee on biological standardization: highlights of the 45th meeting, October 1995. Weekly epidemiological record April 1996, vol. 71:105-108.
40. WHO Expert committee on biological standardization, 46th report 1995, vol. 872. WHO Technical Report Series.
41. Hussain A., Shanmugam V., Switzer W.M., Tsang S.X., Fadly A., Thea D., et al. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients. Emerg Infect Dis 2001, 7(1):66-72.
42. Unexpected protein found in measles-mumps vaccine - entity said to be from chickens, harmless to humans Saturday 9th December 1995, Washington Post.
43. Reverse transcriptase activity in vaccines WHO drug information 1998, vol. 12:140-141.
44. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, etal. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus, J Virol, doi:. doi:10.1128/JVI.02690-09.
45. McClenahan S.D., Krause P.R., Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine 2011, 29(29-30):4745-4753.
46. Baylis S.A., Finsterbusch T., Bannert N., Blümel J., Mankertz A. Analysis of porcine circovirus type 1 detected in rotarix vaccine. Vaccine 2011, 29:690-697.
47. http://www.who.int/vaccine_safety/topics/rotavirus/rotarix_statement_march_2010/en/index.html.
48. http://www.who.int/immunization/Interim_report_Flu_Rotarix_16_Apr_draft_v1.pdf.
49. http://www.who.int/immunization/newsroom/news_rotavirus_vaccine_use/en/index.html.
50. http://www.who.int/wer/2010/wer8522.pdf.
51. http://www.who.int/immunization_standards/vaccine_quality/PCV1_questions_answers_21apr10.pdf.
52. http://www.who.int/vaccine_safety/committee/reports/Jun_2010/en/.
53. Hattermann K., Roedner C., Schmitt C., Finsterbusch T., Steinfeldt T., Mankertz A. Infection studies on human cell lines with porcine circovirus type 1 and porcine circovirus type 2. Xenotransplantation 2004, 11(3):284-294.
54. Burbelo P.D., Ragheb J.A., Kapoor A., Zhang Y. The serological evidence in humans supports a negligible risk of zoonotic infection from porcine circovirus type 2. Biologicals 2013, 41(6):430-434.
55. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001059.jsp%26mid=WC0b01ac058004d5c1.
56. Hattermann K., Maerz A., Slanina H., Schmitt C., Mankertz A. Assessing the risk potential of porcine circoviruses for xenotransplanation: consensus primer-PCR-based search for a human circovirus. Xenotransplantation 2004, 11(6):547-550.